瑞舒伐他汀治疗冠心病合并高血压患者的临床疗效及对血脂水平的影响

Clinical efficacy of rosuvastatin on patients with coronary heart disease and hypertension and its influence on blood lipid

目的 分析瑞舒伐他汀治疗冠心病合并高血压患者的临床疗效及对血脂水平的影响。方法 80例冠心病合并高血压患者,采用随机数字表法分为参照组及试验组,每组40例。参照组患者给予常规治疗,试验组患者在常规治疗的基础上联合瑞舒伐他汀治疗。比较两组患者治疗前后的舒张压、收缩压、心功能等级、血脂指标[总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)]水平,治疗效果,不良反应发生情况。结果 治疗后,两组患者的舒张压、收缩压、心功能等级均低于本组治疗前,且试验组患者的舒张压、收缩压、心功能等级分别为(78.13±3.16)mm Hg(1 mm Hg=0.133 kPa)、(120.02±2.16)mm Hg、(1.41±0.12)级,均低于参照组的(85.25±4.12)mm Hg、(135.13±2.12)mm Hg、(2.21±0.21)级,差异具有统计学意义(P<0.05)。治疗后,两组患者的TC、LDL-C、TG均低于本组治疗前,HDL-C高于本组治疗前,且试验组患者的TC(3.02±0.11)mmol/L、LDL-C(2.72±0.58)mmol/L、TG(1.15±0.58)mmol/L均低于参照组的(5.67±0.12)、(4.14±0.61)、(1.82±0.43)mmol/L,HDL-C(2.46±0.38)mmol/L高于参照组的(1.46±0.45)mmol/L,差异具有统计学意义(P<0.05)。试验组总有效率95.00%高于参照组的75.00%,差异具有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 常规治疗联合瑞舒伐他汀治疗冠心病合并高血压的效果确切,可改善心功能、血脂指标,降低血压水平,值得推广。

Objective To analyze the clinical efficacy of rosuvastatin on patients with coronary heart disease and hypertension and its influence on blood lipid.Methods A total of 80 patients with coronary heart disease and hypertension were randomly divided into the reference group and the experimental group according to random numerical table,with 40 cases in each group.Patients in the reference group were treated with conventional therapy,and patients in the experimental group were treated with rosuvastatin on the basis of conventional therapy.Both groups were compared in terms of diastolic blood pressure,systolic blood pressure,heart function level,blood lipid indexes[total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),triglycerides(TG),high density lipoprotein cholesterol(HDL-C)]before and after treatment,therapeutic effect,and occurrence of adverse reactions.Results After treatment,the diastolic blood pressure,systolic blood pressure,and heart function level of the two groups were lower than those of this group before treatment;the diastolic blood pressure,systolic blood pressure,and heart function level of the experimental group were(78.13±3.16)mm Hg(1 mm Hg=0.133 kPa),(120.02±2.16)mm Hg,(1.41±0.12)grades,which were lower than(85.25±4.12)mm Hg,(135.13±2.12)mm Hg,(2.21±0.21)grades of the reference group;all the differences were statistically significant(P<0.05).After treatment,the TC,LDL-C,and TG of the two groups were lower than those of this group before treatment,and the HDL-C was higher than that of this group before treatment;the TC(3.02±0.11)mmol/L,LDL-C(2.72±0.58)mmol/L and TG(1.15±0.58)mmol/L of the experimental group were lower than(5.67±0.12),(4.14±0.61),and(1.82±0.43)mmol/L of the reference group,and the HDL-C(2.46±0.38)mmol/L was higher than(1.46±0.45)mmol/L of the reference group;all the differences were statistically significant(P<0.05).The total effective rate 95.00%in the experimental group was higher than 75.00%in the reference group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Conventional therapy in combination with rosuvastatin has definite effect on patients with coronary heart disease and hypertension,and it can improve the heart function and blood lipid indexes,and lower the blood pressure level of patients,which is worth popularizing.